Shenyang Hongqi Pharmaceutical: Summary

Shenyang Hongqi Pharmaceutical

Pharmaceutical, Healthcare, Infectious Disease Treatment, Anti-Tuberculosis Medications

To provide effective and innovative anti-tuberculosis medications that improve the quality of life for patients worldwide.

Shenyang Hongqi Pharmaceutical specializes in the research, production, and sales of anti-tuberculosis drugs. As a subsidiary of Shanghai Fosun Pharmaceutical Group, it aims to provide innovative solutions for tuberculosis patients globally.

Rich variety of first-line anti-tuberculosis drugs; Development of second-line multi-drug resistant tuberculosis medications; Compliance with WHO PQ standards for drug production; Significant investment in R&D, accounting for 7.65% of sales revenue

Primarily valuable for healthcare providers treating tuberculosis patients, pharmaceutical distributors, and public health organizations focused on infectious disease control.

Strong R&D capabilities with a focus on innovative drug development; Established production lines that meet WHO PQ standards; Part of a larger, reputable pharmaceutical group (Fosun Pharmaceutical) which enhances credibility and resources

A long-standing commitment to combating tuberculosis, significant investment in research and development, and a robust product line that meets international standards.

Positions itself as a leader in the anti-tuberculosis drug market, focusing on innovation and quality to address global health challenges.

Healthcare professionals, pharmaceutical distributors, and public health organizations, particularly those involved in tuberculosis treatment and prevention.

Join Hongqi Pharmaceutical

• anti-tuberculosis

• pharmaceutical

• healthcare

• innovation

Let humanity no longer be troubled by tuberculosis

Professional, compassionate, innovative

Focus on both first-line and second-line anti-tuberculosis drugs, with a commitment to global health and adherence to international quality standards.

A reputable pharmaceutical brand dedicated to improving health outcomes for tuberculosis patients, backed by the resources of a major pharmaceutical group.

1964-01-01